Open Access
Open access
том 31 издание 14 страницы 1100-1129

Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update)

Тип публикацииJournal Article
Дата публикации2025-04-01
SCImago Q2
WOS Q2
БС2
SJR0.632
CiteScore5.9
Impact factor2.8
ISSN13816128, 18734286
Краткое описание
Abstract:

The pyrimidine nucleus is a fundamental component of human DNA and RNA, as well as the backbone of many therapeutic agents. Its significance in medicinal chemistry is well-established, with pyrimidine derivatives receiving considerable attention due to their potent anticancer properties across various cancer cell lines. Numerous derivatives have been synthesized, drawing structural inspiration from known anticancer agents like dihydropyrimidine compounds, which include the active cores of drugs such as 5-fluorouracil and monastrol, both of which have demonstrated strong anticancer efficacy. Additionally, various pyrimidine derivatives have been developed through different synthetic pathways, exhibiting promising anticancer potential. In response to the growing need for effective cancer treatments, recent efforts have focused on synthesizing and exploring novel pyrimidine derivatives with improved efficacy and specificity. This review aims to highlight the versatility of pyrimidine-based compounds in cancer therapy, emphasizing not only their potency and binding affinity but also their optimal interaction with diverse biological targets. The goal is to facilitate the design of new pyrimidine derivatives with enhanced anticancer potential, providing effective solutions for the treatment of various cancer types.

Для доступа к списку цитирований публикации необходимо авторизоваться.

Топ-30

Журналы

1
2
RSC Medicinal Chemistry
2 публикации, 15.38%
Future Medicinal Chemistry
2 публикации, 15.38%
Journal of Molecular Structure
2 публикации, 15.38%
Chemistry and Biodiversity
1 публикация, 7.69%
Medicinal Chemistry Research
1 публикация, 7.69%
Bioorganic and Medicinal Chemistry
1 публикация, 7.69%
Bioorganic Chemistry
1 публикация, 7.69%
ChemistrySelect
1 публикация, 7.69%
Archiv der Pharmazie
1 публикация, 7.69%
Russian Chemical Reviews
1 публикация, 7.69%
1
2

Издатели

1
2
3
4
Elsevier
4 публикации, 30.77%
Wiley
3 публикации, 23.08%
Royal Society of Chemistry (RSC)
2 публикации, 15.38%
Taylor & Francis
2 публикации, 15.38%
Springer Nature
1 публикация, 7.69%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 7.69%
1
2
3
4
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
13
Поделиться
Цитировать
ГОСТ |
Цитировать
Zeid M. M. et al. Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update) // Current Pharmaceutical Design. 2025. Vol. 31. No. 14. pp. 1100-1129.
ГОСТ со всеми авторами (до 50) Скопировать
Zeid M. M., Elbadry O. M., Elmeligie S., Hassan R. A. Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update) // Current Pharmaceutical Design. 2025. Vol. 31. No. 14. pp. 1100-1129.
RIS |
Цитировать
TY - JOUR
DO - 10.2174/0113816128346900241111115125
UR - https://www.eurekaselect.com/238021/article
TI - Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update)
T2 - Current Pharmaceutical Design
AU - Zeid, Mai M.
AU - Elbadry, Osama M.
AU - Elmeligie, Salwa
AU - Hassan, Rasha A.
PY - 2025
DA - 2025/04/01
PB - Bentham Science Publishers Ltd.
SP - 1100-1129
IS - 14
VL - 31
PMID - 39773052
SN - 1381-6128
SN - 1873-4286
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2025_Zeid,
author = {Mai M. Zeid and Osama M. Elbadry and Salwa Elmeligie and Rasha A. Hassan},
title = {Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update)},
journal = {Current Pharmaceutical Design},
year = {2025},
volume = {31},
publisher = {Bentham Science Publishers Ltd.},
month = {apr},
url = {https://www.eurekaselect.com/238021/article},
number = {14},
pages = {1100--1129},
doi = {10.2174/0113816128346900241111115125}
}
MLA
Цитировать
Zeid, Mai M., et al. “Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update).” Current Pharmaceutical Design, vol. 31, no. 14, Apr. 2025, pp. 1100-1129. https://www.eurekaselect.com/238021/article.
Ошибка в публикации?